Cervical cancer primary prevention: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
Line 4: Line 4:


==Overview==
==Overview==
Prevention of cervical cancer includes a comprehensive approach involving awareness, screening, and preventative vaccinations.
Most effective and cost efficient primary prevention available for cervical cancer is vaccination against high risk strains of human papilloma virus, which are HPV 16 and 18 and is given to adoloscent and young women ideally before the sexual debut.  


==Primary Prevention==
==Primary Prevention==
 
:Primary prevention method for cervical cancer is vaccination against HPV types 16 and 18, there are two type of FDA approved vaccines available in the market. These vaccines are most effective when it's given to women age 9 to 26 and young male population through age 21 according to CDC recommendation. <ref name="MarkowitzUnger2009">{{cite journal|last1=Markowitz|first1=L. E.|last2=Unger|first2=E. R.|last3=Saraiya|first3=M.|title=Primary and Secondary Prevention of Cervical Cancer--Opportunities and Challenges|journal=JNCI Journal of the National Cancer Institute|volume=101|issue=7|year=2009|pages=439–440|issn=0027-8874|doi=10.1093/jnci/djp044}}</ref>
'''Delay sex''': Waiting to have sex until you are older can help you avoid HPV.
:HPV vaccine also is recommended for following target poulation:
 
:* Young homosexual or bisexual men who have sex with men through age 26
'''Use condoms:''' Condoms provide some protection against HPV.
:* HIV infected young adult who have weakened immune system through age 26
 
:* Young adults who are transgender through age 26
'''Avoidance of smoking:'''Clinical survey show no smoking is another important way to reduce the risk of cervical precancer and cancer.
:
 
:The trade name of the available FDA approved vaccines include: <ref name="pmid19895230">{{cite journal |vauthors=Grce M |title=Primary and secondary prevention of cervical cancer |journal=Expert Rev. Mol. Diagn. |volume=9 |issue=8 |pages=851–7 |date=November 2009 |pmid=19895230 |doi=10.1586/erm.09.64 |url=}}</ref>
'''Get vaccinated:''' Vaccines have been developed that can protect women from HPV infections.
:* Gardasil, quadrivalent vaccine, composed of HPV 6, 11, 16 and 18.  
 
:* Cervarix, bivalent vaccine, composed of HPV 16 and 18.  
'''Regular gynecological examinations'''
:*[[Pap test]]
:*Treatment of precancerous abnormalities
 
===Awareness===
According to the US [[National Cancer Institute]]'s 2005 Health Information National Trends survey, only 40% of American women surveyed had heard of human papillomavirus (HPV) infection and only 20% had heard of its link to cervical cancer.<ref>{{cite web|url =http://www.msnbc.msn.com/id/15713966/|title=Most women unaware about HPV (MSNBC)}}</ref> In 2006 an estimated 10,000 women in the US will be diagnosed with this type of cancer and nearly 4,000 will die from it.<ref>[http://www.cancer.org/docroot/CRI/content/CRI_2_4_1X_What_are_the_key_statistics_for_cervical_cancer_8.asp?sitearea=]</ref>
===Vaccination===
*'''HPV vaccine'''
 
[[Merck & Co.]] has developed a vaccine against four strains of HPV (6,11,16,18), called [[Gardasil]]™. It is now on the market after receiving approval from the US Food and Drug Administration on June 8, 2006.<ref>[http://www.fda.gov/bbs/topics/NEWS/2006/NEW01385.html]</ref> Gardasil is targeted at girls and women of age 9 to 26 because the vaccine only works if given before infection occurs; therefore, public health workers are targeting girls before they begin having sex. The use of the vaccine in men to prevent genital warts and interrupt transmission to women is initially considered only a secondary market. The high cost of this vaccine has been a cause for concern. Gardasil has also been approved in the EU.<ref>BBC [http://news.bbc.co.uk/1/hi/health/5370504.stm EU approves cervical cancer jab] 22 September 2006</ref>
 
[[GlaxoSmithKline]] has developed a vaccine called [[Cervarix]]™ which has been shown to be 100% effective in preventing HPV strains 16 and 18 and is 100% effective for more than four years.<ref>[http://www.medicalnewstoday.com/medicalnews.php?newsid=38317]</ref>
These strains together cause about 70% of cervical cancer cases. Cervarix should be approved by year's end.<ref>The Grand Rapids Press [http://www.mlive.com/news/grpress/index.ssf?/base/news-31/1155818704291630.xml&coll=6 About the cervical cancer vaccine] 17 August 2006</ref><ref>BBC [http://news.bbc.co.uk/1/hi/health/5311598.stm Cancer jab 'stops 75% of deaths'] 4 September 2006</ref>
 
Neither Merck & Co. nor GlaxoSmithKline invented the vaccine. The vaccine's key developmental steps are claimed by the [[National Cancer Institute]] in the US, the University of Rochester in New York, Georgetown University in Washington, DC, and the Queensland University in Brisbane, Australia. Both Merck & Co. and GlaxoSmithKline have licensed patents from all of these parties.<ref>[http://jnci.oxfordjournals.org/cgi/content/full/98/7/433]</ref>
 
===Other Possible Preventive Measures===
A study published in 2002 (Castellsagué ''et al'') reports that male circumcision can reduce the risk of penile HPV infection in a man, and so the risk of cervical cancer in his female partner. The authors state that "it would not make sense to promote circumcision as a way to control cervical cancer in the US, where Pap smears usually detect it at a treatable stage".  However, Menczer (2004) quotes research that male circumcision probably does not contribute to a lower incidence of cervical cancer in Jewish populations.
 
One study suggests that [[prostaglandin]] in [[semen]] may fuel the growth of cervical and uterine tumours and that affected women may benefit from the use of [[condom]]s.<ref>BBC [http://news.bbc.co.uk/1/hi/health/5303054.stm Semen 'may fuel cervical cancer'] 31 August 2006</ref><ref>[[Medical Research Council (UK)|Medical Research Council]] [http://www.mrc.ac.uk/NewsViewsAndEvents/News/MRC002621 Semen can worsen cervical cancer]</ref>


==References==
==References==

Revision as of 15:29, 14 February 2019

Cervical cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cervical Cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Cervical Cancer During Pregnancy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cervical cancer primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cervical cancer primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cervical cancer primary prevention

CDC on Cervical cancer primary prevention

Cervical cancer primary prevention in the news

Blogs on Cervical cancer primary prevention

Directions to Hospitals Treating Cervical cancer

Risk calculators and risk factors for Cervical cancer primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Most effective and cost efficient primary prevention available for cervical cancer is vaccination against high risk strains of human papilloma virus, which are HPV 16 and 18 and is given to adoloscent and young women ideally before the sexual debut.

Primary Prevention

Primary prevention method for cervical cancer is vaccination against HPV types 16 and 18, there are two type of FDA approved vaccines available in the market. These vaccines are most effective when it's given to women age 9 to 26 and young male population through age 21 according to CDC recommendation. [1]
HPV vaccine also is recommended for following target poulation:
  • Young homosexual or bisexual men who have sex with men through age 26
  • HIV infected young adult who have weakened immune system through age 26
  • Young adults who are transgender through age 26
The trade name of the available FDA approved vaccines include: [2]
  • Gardasil, quadrivalent vaccine, composed of HPV 6, 11, 16 and 18.
  • Cervarix, bivalent vaccine, composed of HPV 16 and 18.

References

  1. ↑ Markowitz, L. E.; Unger, E. R.; Saraiya, M. (2009). "Primary and Secondary Prevention of Cervical Cancer--Opportunities and Challenges". JNCI Journal of the National Cancer Institute. 101 (7): 439–440. doi:10.1093/jnci/djp044. ISSN 0027-8874.
  2. ↑ Grce M (November 2009). "Primary and secondary prevention of cervical cancer". Expert Rev. Mol. Diagn. 9 (8): 851–7. doi:10.1586/erm.09.64. PMID 19895230.

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Cervical_cancer_primary_prevention&oldid=1550001"